

AMENDMENT

In the Claims:

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1-33. (Cancelled)

34-74. (Cancelled)

75. (Currently amended) ~~The polypeptide of claim 33, wherein the coding sequence encodes a first polypeptide comprising a first~~ An isolated protein comprising:

(a) a first polypeptide domain comprising an ordered arrangement of three complementarity determining regions (CDRs) interposed between framework regions (FRs), said FRs derived from a human immunoglobulin, wherein the first polypeptide domain comprises an amino acid sequence of the general formula FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 and;

(b) ~~a second polypeptide comprising a second~~ a second polypeptide domain comprising an ordered arrangement of three CDRs interposed between FRs, said FRs derived from a human immunoglobulin, wherein the second polypeptide domain comprises an amino acid sequence of the general formula FR1'-CDR1'-FR2'-CDR2'-FR3'-CDR3'-FR4',

~~wherein FR1, FR2, FR3, FR4, FR1', FR2', FR3' and FR4' are framework regions and each of CDR1, CDR2, CDR3, CDR1', CDR2' and CDR3' is a sequence of amino acids with at least 90% sequence identity to the sequence of amino acids found at amino acid positions 31-35 of SEQ ID NO:6, the sequence of amino acids found at amino acid positions 50-66 of SEQ ID NO:6, the sequence of amino acids found at amino acid positions 99-104 of SEQ ID NO:6, the sequence of amino acids found at amino acid positions 157-167 of SEQ ID NO:6, the sequence of amino acids found at amino acid~~

positions 183-189 of SEQ ID NO:6 and the sequence of amino acids found at amino acid positions 222-230 of SEQ ID NO:6, respectively, and further wherein said first and second polypeptide domains together are capable of forming a binding site for c-erbB-2.

76. (Cancelled)

77. (Currently amended) The polypeptide protein of claim ~~76~~ 75, wherein each of CDR1, CDR2, CDR3, CDR1', CDR2' and CDR3' is the sequence of amino acids found at amino acid positions 31-35 of SEQ ID NO:6, the sequence of amino acids found at amino acid positions 50-66 of SEQ ID NO:6, the sequence of amino acids found at amino acid positions 99-104 of SEQ ID NO:6, the sequence of amino acids found at amino acid positions 157-167 of SEQ ID NO:6, the sequence of amino acids found at amino acid positions 183-189 of SEQ ID NO:6 and the sequence of amino acids found at amino acid positions 222-230 of SEQ ID NO:6, respectively;
~~——— and further wherein said first and second polypeptides together are capable of forming an antibody immunologically reactive with c-erbB-2.~~

78. (Currently amended) The polypeptide protein of claim 77, wherein said first and second polypeptides together are capable of forming a humanized antibody.

79. (Currently amended) The polypeptide protein of claim 78, wherein said FR sequences are human immunoglobulin framework region sequences of a human myeloma antibody.

80. (New) The protein of claim 75, wherein the first and second polypeptide domains are linked by a polypeptide linker.

81. (New) The protein of claim 80, wherein the polypeptide linker comprises at least 10 amino acids.

82. (New) The protein of claim 81, wherein the polypeptide linker comprises the sequence of SEQ ID NO:7 or SEQ ID NO:8.

83. (New) The protein of claim 77, wherein the first and second polypeptide domains are linked by a polypeptide linker.

84. (New) The protein of claim 83, wherein the polypeptide linker comprises at least 10 amino acids.

85. (New) The protein of claim 84, wherein the polypeptide linker comprises the sequence of SEQ ID NO:7 or SEQ ID NO:8.

86. (New) The protein of claim 84, comprising the sequence of amino acids of SEQ ID NO:6.